Login to Your Account

New drug class shows promise against TB in preclinical testing

By John Fox
Staff Writer

Wednesday, December 11, 2013

HONG KONG – A novel class of antitubercular drugs, the indol carboxamides, has been shown safe and effective against clinical Mycobacterium tuberculosis isolates in preclinical studies, report Novartis Institute for Tropical Diseases (NITD) in Singapore researchers in the latest issue of Science Translational Medicine.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription